New method may halt Alzheimer's disease

Researchers have discovered a new method that may halt the progression of dementia caused by accumulation of a protein known as tau.
Normally, tau protein is involved in microtubule formation, which acts as a brain cell's transportation system for carrying nutrients in and waste out.
In the absence of tau protein, brain cells become dysfunctional and eventually die, said researchers at the University of Texas Medical Branch at Galveston.
In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications.

Without the ability of brain cells to receive signals, they become severely dysfunctional and if enough of them die in a given area of the brain, the result is cognitive impairment, which means difficulty in planning tasks and remembering things.
This accumulation of tau results in the formation of tau oligomers, the toxic form of tau protein.

Scientists believe that if you can get rid of this toxic oligomeric tau protein, you can potentially stop the spread of tau-related dementia.
The trick is to remove the toxic oligomeric tau without also removing the normal, functional tau protein.
Researchers did just that and demonstrated that treatment with their tau oligomer-specific monoclonal antibody, called TOMA, in experiments involving a rodent model of tauopathy (tau-related dementia) improved locomotor function and performance on memory tests.

The TOMA antibody sticks to the oligomeric tau so it can no longer interfere with cell-to-cell communication, but leaves the native tau protein intact.
"This is significant because this research describes a very promising vaccination strategy for Alzheimer's disease, which could prevent memory loss from occurring later in life," said professor Rakez Kayed, senior author of the study.
"No safety concerns were detected in mice receiving this treatment, but more research is needed to confirm the efficacy and safety of immunisation in other animals and in humans," said Kayed.
The study was published in the Journal of Neuroscience.